Table 1 The clinical characteristics of patients with HCC

Age^a (years)

53.0 ± 11.6

50.8 ± 11.5

54.5 ± 11.4

0.004

Sex (n, %)

0.359

 Male

283 (84.7%)

120 (87.0%)

163 (83.2%)

 Female

51 (15.3%)

18 (13.0%)

33 (16.8%)

AFP ^b (ng/mL)

23.1 (1.1–2112.0)

19.9 (1.1–2112.0)

26.6 (1.3–1210.0)

0.344

CA199^b (U/mL)

16.4 (1.0–1000.0)

15.2 (1.0–1000.0)

17.4 (1.0–1000.0)

0.375

CEA^b (ng/mL)

2.2 (1.0–16.0)

2.1 (1.0–7.0)

2.3 (1.0–16.0)

0.076

TBIL^b (μmol/L)

14.8 (5.2–537.7)

14.6 (5.2–537.7)

14.9 (5.3–499.2)

0.395

DBIL^b (μmol/L)

5.2 (1.0–424.0)

5.1 (1.5–418.8)

5.3 (1.0–424.0)

0.112

IBIL^b (μmol/L)

9.5 (3.0–118.9)

9.3 (3.0–118.9)

9.6 (3.5–75.2)

0.625

ALT^b (U/L)

34.0 (10.0–753.0)

32.0 (10.0–753.0)

34.0 (11.0–607.0)

0.770

AST^b (U/L)

32.0 (14.0–845.0)

31.0 (16.0–845.0)

33.5 (14.0–450.0)

0.972

ALB^b (g/L)

44.5 (23.1–147.0)

44.8 (31.2–147.0)

44.4 (23.1–55.3)

0.193

PLT^b (10⁹/L)

125.0 (25.0–470.0)

136.0 (25.0–285.0)

120.0 (26.0–470.0)

0.060

Cause of liver disease

0.524

 HBV

269 (80.5%)

115 (83.4%)

154 (78.6%)

 HCV

2 (0.6%)

1 (0.7%)

1 (0.5%)

 HBV + HCV

21 (6.3%)

9 (6.5%)

12 (6.1%)

 OTHER^c

42 (12.6%)

13 (9.4%)

29 (14.8%)

BCLC stage

0.834

 0

70 (21.0%)

29 (21.0%)

41 (20.9%)

 A

226 (67.7%)

95 (68.9%)

131 (66.9%)

 C

38 (11.3%)

14 (10.1%)

24 (12.2%)